UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

Journal of Immunology Research, 2016-01, Vol.2016 (2016), p.1-8

2016

Volltextzugriff (PDF)

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

PloS one, 2017-12, Vol.12 (12), p.e0189953-e0189953

2017

Volltextzugriff (PDF)

Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib

PloS one, 2015-06, Vol.10 (6), p.e0130700-e0130700

2015

Volltextzugriff (PDF)

Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling

Journal for immunotherapy of cancer, 2022-07, Vol.10 (7), p.e005113

2022

Volltextzugriff (PDF)

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

The Journal of experimental medicine, 2004-01, Vol.199 (1), p.125-130

2004

Volltextzugriff (PDF)

Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma

Clinical cancer research, 2005-02, Vol.11 (3), p.1181-1189

2005

Volltextzugriff (PDF)

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Blood, 2007-04, Vol.109 (8), p.3177-3188

2007

Volltextzugriff (PDF)

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

Journal of thoracic oncology, 2009-08, Vol.4 (8), p.1002-1009

2009

Volltextzugriff (PDF)

Interleukin-11: A gp130 Cytokine

Annals of the New York Academy of Sciences, 1998-09, Vol.856 (1), p.12-21

1998

Volltextzugriff (PDF)

Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition

Journal of immunological methods, 2011-01, Vol.363 (2), p.135-142

2011

Volltextzugriff (PDF)

Validation of a flow cytometry based G₂M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition

Journal of immunological methods, 2011-01, Vol.363 (2), p.135-142

2011

Volltextzugriff (PDF)

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

The Journal of clinical investigation, 1999-12, Vol.104 (11), p.1527-1537

1999

Volltextzugriff (PDF)

Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma

Cancer research (Chicago, Ill.), 2003-09, Vol.63 (18), p.6069-6075

2003

Volltextzugriff (PDF)

Protective Effect of rhIL-11 in a Murine Model of Acetaminophen-Induced Hepatotoxicity

Toxicologic pathology, 2001-03, Vol.29 (2), p.242-249

2001

Volltextzugriff (PDF)

Pharmacogenomic data submissions to the FDA: clinical case studies

Pharmacogenomics, 2004-07, Vol.5 (5), p.519-524

2004

Volltextzugriff (PDF)

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

JMIR research protocols, 2017-03, Vol.6 (3), p.e45-e45

2017

Volltextzugriff (PDF)

Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis

Molecular medicine (Cambridge, Mass.), 2007-01, Vol.13 (1-2), p.40-58

2007

Volltextzugriff (PDF)

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

The Lancet (British edition), 2017-08, Vol.390 (10094), p.555-566

2017

Volltextzugriff (PDF)

Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells

Journal of interferon & cytokine research, 2001-01, Vol.21 (1), p.21-30

2001

Volltextzugriff (PDF)

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS2684-TPS2684

2024

Volltextzugriff (PDF)

Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials

Current molecular medicine, 2005-02, Vol.5 (1), p.83-102

2005

Volltextzugriff (PDF)

Exploiting genotypic differences to identify genes important for EAE development

Journal of the neurological sciences, 2005-12, Vol.239 (1), p.81-93

2005

Volltextzugriff (PDF)

Abstract B1-59: Identification of key molecular characteristics for achieving increased anti-tumor activity by combined mTORC1/2 and MEK1/2 investigational agents

Cancer research (Chicago, Ill.), 2015-11, Vol.75 (22_Supplement_2), p.B1-B1-59

2015

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(53)

Publikationsform

Artikel
(60)
Buchkapitel
(1)

Sprache

Englisch
(61)

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(30)
Humans
(28)
Female
(17)
Biological And Medical Sciences
(12)
Animals
(11)
Mice
(10)
Immunology
(9)
Male
(9)
Medical Sciences
(9)
Adult
(8)
Oncology
(7)
Aged
(6)
Base Sequence
(6)
Biomarkers
(6)
Middle Aged
(6)
Oligonucleotide Array Sequence Analysis
(6)
Recombinant Proteins - Pharmacology
(6)
Biochemistry & Molecular Biology
(5)
Flow Cytometry
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance

Consistent expression of guanylyl cyclase-C in primary and metastatic gastrointestinal cancers

Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib

Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling

Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris

Transcriptional Profiles in Peripheral Blood Mononuclear Cells Prognostic of Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma

Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer

Interleukin-11: A gp130 Cytokine

Validation of a flow cytometry based G(2)M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition

Validation of a flow cytometry based G₂M delay cell cycle assay for use in evaluating the pharmacodynamic response to Aurora A inhibition

Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions

Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma

Protective Effect of rhIL-11 in a Murine Model of Acetaminophen-Induced Hepatotoxicity

Pharmacogenomic data submissions to the FDA: clinical case studies

Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

Molecular profile of peripheral blood mononuclear cells from patients with rheumatoid arthritis

Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial

Interleukin-11 modulates Th1/Th2 cytokine production from activated CD4+ T cells

A phase 1/2, first-in-human, open-label, dose-escalation study of TAK-280, an investigational B7-H3 x CD3ε conditional bispecific redirected activation (COBRA) T-cell engager, in adult patients with unresectable, locally advanced, or metastatic solid tumors

Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials

Exploiting genotypic differences to identify genes important for EAE development

Abstract B1-59: Identification of key molecular characteristics for achieving increased anti-tumor activity by combined mTORC1/2 and MEK1/2 investigational agents

Suchergebnisse filtern